Kronos Bio Inc is a biotechnology business based in the US. Kronos Bio Inc shares (KRON) are listed on the NASDAQ and all prices are listed in US Dollars. Kronos Bio Inc employs 96 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.74 |
|---|---|
| 52-week range | $2.96 - $25.76 |
| 50-day moving average | $4.25 |
| 200-day moving average | $10.93 |
| Wall St. target price | $22.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.92 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.74 from 2022-06-29
| 1 week (2022-06-23) | 4.47% |
|---|---|
| 1 month (2022-06-01) | 8.41% |
| 3 months (2022-04-01) | -49.12% |
| 6 months (2021-12-31) | -72.48% |
| 1 year (2021-07-01) | -84.63% |
|---|---|
| 2 years (2020-06-27) | N/A |
| 3 years (2019-06-27) | N/A |
| 5 years (2017-06-27) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -23.66% |
| Return on equity TTM | -42.31% |
| Profit margin | 0% |
| Book value | $5.66 |
| Market capitalisation | $203.1 million |
TTM: trailing 12 months
We're not expecting Kronos Bio Inc to pay a dividend over the next 12 months.
Kronos Bio Inc's shares were split on a 3:2 basis on 2 November 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Kronos Bio Inc shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Kronos Bio Inc shares which in turn could have impacted Kronos Bio Inc's share price.
Kronos Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
